Check out today's top analyst calls from around Wall Street, compiled by The Fly.
VBI VACCINES MAY HAVE BEST COVID VACCINE: Raymond James analyst Steven Seedhouse upgraded VBI Vaccines (VBIV) to Strong Buy from Outperform with a price target of $9, up from $8, following first look data for VBI's COVID-19 vaccine. Seedhouse tells investors in a research note that the vaccine looks like it could be the best vaccine of them all, including all of the first movers and Operation Warp Speed members.
DICK'S SPORTING GETS UPGRADE AND DOWNGRADE AFTER EARNINGS: Oppenheimer analyst Brian Nagel downgraded Dick's Sporting Goods (DKS) to Perform from Outperform with a $56 price target, up from $52. Nagel says that while he admires the efforts of management to thrive amid consumer sector upheaval, he looks upon stronger sales and earnings lately as largely shorter-term in nature and are hard-pressed to envision the market awarding shares a meaningfully higher multiple.
Meanwhile, Morgan Stanley analyst Simeon Gutman upgraded Dick's Sporting to Overweight from Equal Weight with a price target of $65, up from $40. He sees gross margin expansion and significant share repurchases driving earnings upside over the next two years that he believes is underappreciated, said Gutman, who notes that his 2021 EPS estimates are 10% above consensus and his 2022 forecast is 30% better than consensus.
GROWGENERATION GETS STREET-HIGH TARGET: Stifel analyst W. Andrew Carter initiated coverage of GrowGeneration (GRWG) with a Buy rating and $22 price target. The shares are currently undervaluing the company's "differentiated growth profile" as the leading specialty retailer of hydroponics, the potential value creation from the ongoing roll-up opportunity, and the scarcity value of pure-play investable opportunities for capitalizing on the growth of the U.S. cannabis category, Carter tells investors in a research note. The analyst estimates GrowGeneration can post 55% annual revenue growth through fiscal 2022.
PELOTON EXPECTATIONS 'FAR TOO LOW': Goldman Sachs analyst Heath Terry raised the firm's price target on Peloton (PTON) to $96 from $84 and keeps a Buy rating on the shares, citing his view that expectations for Peloton's growth and profitability are still "far too low," both in the near and long term. The company's doubling of production and weeks long order backlog that has persisted through the pandemic, all without any material marketing spend, isn't simply a pull forward, but represents an acceleration and steepening of the adoption curve in a fitness landscape that has fundamentally altered, argues Terry, who has raised his Peloton estimate ahead of the company's Q4 report due on September 10.
PERSONALIS INITIATED WITH A BUY: H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Personalis (PSNL) with a Buy rating and $30 price target. The company is a developer of next generation sequencing technologies and comprehensive molecular profiling platforms, Ramakanth tells investors in a research note. With an "ever-increasing" demand for comprehensive genetic information by the drug industry, Personalis is poised for sustained growth and at current valuation of $698M, is an attractive opportunity for a long-term investors, says the analyst.
VBI Vaccines
-0.07 (-2.14%)
Dick's Sporting
+7.33 (+15.71%)
GrowGeneration
-0.82 (-5.50%)
Peloton
+0.75 (+1.13%)
Personalis
+0.73 (+3.45%)